Supplementary report: surveillance of adverse events following immunisation among children aged less than seven years in Australia, 1 January to 30 June 2009

Authors

  • Deepika Mahajan National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, University of Sydney and The Children’s Hospital at Westmead, Sydney, New South Wales
  • Rob Menzies National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, University of Sydney and The Children’s Hospital at Westmead, Sydney, New South Wales
  • Ilnaz Roomiani Office of Medicine Safety Monitoring, Therapeutic Goods Administration, Canberra, Australian Capital Territory
  • Glenda Lawrence National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, University of Sydney and The Children’s Hospital at Westmead, Sydney, New South Wales; School of Public Health and Community Medicine, University of New South Wales, Sydney, New South Wales

DOI:

https://doi.org/10.33321/cdi.2010.34.7

Keywords:

AEFI, surveillance, immunisation, vaccine safety

Abstract

The adverse events following immunisation surveillance aims to monitor vaccine and immunisation program safety and to detect population-specific, rare, late-onset or unexpected adverse events that may not be detected in pre-licensure vaccine trials. This report summarises national passive surveillance data reported to 31 August 2009 for adverse events following immunisation (AEFI) in children aged less than 7 years who received vaccines between 1 January and 30 June 2009.

Downloads

Download data is not yet available.

References

National Health and Medical Research Council. The Australian Immunisation Handbook. 9th edn. Canberra: Australian Government Department of Health and Ageing, 2008.

Department of health and Human Services, Victoria. Immunisation newsletter. Accessed on January 2009. Available from: http://www.health.vic.gov.au/data/assets/pdffile/0015/130083/immunisation-newsletter-issue-32.pdf

Immunisation section Department of Health, South Australia, Quarterly newsletter. Accessed on January 2009. Available from: http://www.dh.sa.gov.au/pehs/Immunisation/0803-sharp-point-news.pdf

Queensland Department of Health. National Immunisation Program Schedule change for Queensland. Accessed January 2009. Available from: http://www.health.qld.gov.au/ph/Documents/cdb/imm sched gp.pdf

Centers for Disease Control and Prevention. Continued shortage of Haemophilus influenzae type b (Hib) conjugate vaccines and potential implications for Hib surveillance—United States, 2008. MMWR Morb Mortal Wkly Rep 2008;57(46):1252–1255.

Lawrence G, Menzies R, Burgess M, McIntyre P, Wood N, Boyd I, et al. Surveillance of adverse events following immunisation: Australia, 2000–2002. Commun Dis Intell 2003;27(3):307–323.

Lawrence GL, Mahajan D, Roomiani I. Supplementary report: surveillance of adverse events following immunisation among children aged < 7 years in Australia,1 January to 30 June 2008. Commun Dis Intell 2009;33(1):27–31.

Lawrence G, Gold MS, Hill R, Deeks S, Glasswell A, McIntyre PB. Annual report: surveillance of adverse events following immunisation in Australia, 2007. Commun Dis Intell 2008;32(4):371–387.

Lawrence GL, Aratchige PE, Hill R. Supplementary report: surveillance of adverse events following immunisation among children aged < 7 years in Australia, 1 January to 30 June 2007. Commun Dis Intell 2007;31(4):379–382.

Lawrence G, Boyd I. Supplementary report: surveillance of adverse events following immunisation among children aged <7 years in Australia, 1 January to 30 June 2006. Commun Dis Intell 2006;30(4):438–442.

State Government of Victoria, Department of Human Services. SAEFVIC: Surveillance of adverse events following vaccination in the community. State Government of Victoria, 2008. Accessed on September 2009. Available from: http://www.health.vic.gov.au/immunisation/general/saefvic

Pym M, Adams J, Booy R, et al. The development and trial of paediatric active enhanced disease surveillance (PAEDS): A new surveillance mechanism for Australia. Presented at the Royal Australasian College of Physicians Congress, Adelaide, 11–15 May 2008.

Gold MS, Noonan S, Osbourn M, Precepa S, Kempe AE. Local reactions after the fourth dose of acellular pertussis vaccine in South Australia. Med J Aust 2003;179(4):191–194.

Rennels MB, Deloria MA, Pichichero ME, Losonsky GA, Englund JA, Meade BD, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 2000;105(1):e12. Available from: http://pediatrics.aappublications.org/cgi/reprint/105/1/e12.pdf

Kramarz P, France EK, DeStefano F, Black SB, Shinefield H, Ward JI, et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J 2001;20(4):410–416.

Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, et al. Intussusception among infants given an oral rotavirus vaccine. [erratum in N Engl J Med 2001;344(20):1564]. N Engl J Med 2001;344(8):564–572.

Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Costa Clemens S, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354(1):11–22.

Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354(1):23–33.

Downloads

Published

31/03/10

How to Cite

Mahajan, Deepika, Rob Menzies, Ilnaz Roomiani, and Glenda Lawrence. 2010. “Supplementary Report: Surveillance of Adverse Events Following Immunisation Among Children Aged Less Than Seven Years in Australia, 1 January to 30 June 2009”. Communicable Diseases Intelligence 34 (March):49-53. https://doi.org/10.33321/cdi.2010.34.7.

Most read articles by the same author(s)

1 2 3 > >>